STAT3 and cancer: STAT3 is often constitutively activated in various cancers, including breast, lung, and hematological malignancies, with this aberrant activation typically arising from mutations, overexpression of upstream cytokine receptors, or dysregulation of related signaling pathways (He et al. 2022; Wong et al. 2022; Brandstoetter et al. 2023).